Brain scans and blood tests may predict who responds to Fast-Acting depression treatments
NCT ID NCT07602153
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 130 people with major depression who have suicidal thoughts. Researchers will use brain scans, genetic tests, and other biological measures to see how rapid treatments like Esketamine and electroconvulsive therapy (ECT) change the brain. The goal is to find early signs that show which treatment works best for each person, reducing the need for trial-and-error and lowering suicide risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can couples counseling lift depression in women?
- Brain wave clues: could inflammation markers forecast ECT outcomes?
- Can tailored brain zaps beat standard therapy for depression?
- Can a new daily pill lift the fog of depression?
- Can a new pill outsmart depression? a trial puts KH607 to the test
- Depression's biological fingerprint: a quest for objective diagnosis and personalized treatment